Unknown

Dataset Information

0

Activation of Human Natural Killer Cells by Graphene Oxide-Templated Antibody Nanoclusters.


ABSTRACT: An emerging new paradigm is that immune cell activation is controlled by transient interactions between supramolecular assemblies of receptors and ligands. Current immunotherapy biologic pharmaceuticals that activate or desensitize NK cells are, however, individual molecules that do not replicate this nanoscale organization of proteins. Here, we use nanoscale graphene oxide (NGO) as a template to generate soluble nanoscale clusters of Natural Killer cell-activating antibodies. We control nanocluster size and molecular number to mimic reported values for cell surface proteins. These NGO-templated molecular nanoclusters, used to stimulate NK cells via the CD16 receptor, successfully induced cellular activation, indicated by degranulation of cytolytic granules and IFN-? secretion. Importantly, activation significantly exceeded that induced by the same antibodies applied as a solution of individual molecules. These results demonstrate that future immunotherapies could be enhanced by assembling immunomodulatory drugs into nanoclusters and establish NGO-templating as a candidate technology.

SUBMITTER: Loftus C 

PROVIDER: S-EPMC5951604 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activation of Human Natural Killer Cells by Graphene Oxide-Templated Antibody Nanoclusters.

Loftus Christian C   Saeed Mezida M   Davis Daniel M DM   Dunlop Iain E IE  

Nano letters 20180420 5


An emerging new paradigm is that immune cell activation is controlled by transient interactions between supramolecular assemblies of receptors and ligands. Current immunotherapy biologic pharmaceuticals that activate or desensitize NK cells are, however, individual molecules that do not replicate this nanoscale organization of proteins. Here, we use nanoscale graphene oxide (NGO) as a template to generate soluble nanoscale clusters of Natural Killer cell-activating antibodies. We control nanoclu  ...[more]

Similar Datasets

| S-EPMC7893158 | biostudies-literature
| S-EPMC8030727 | biostudies-literature
2011-07-26 | E-GEOD-30950 | biostudies-arrayexpress
| S-EPMC6612093 | biostudies-literature
| S-EPMC6787201 | biostudies-literature
| S-EPMC7940276 | biostudies-literature